GLP-1 Cost and Coverage 2026: Self-Pay, Insurance and Pill Prices

By Dr. Frank Yap, MD  |  Last reviewed: November 2026  |  Purpose: evidence and cost education, not individual medical or financial advice

Quick Answer
In November 2026, advertised US self-pay prices for weight-management GLP-1s start at $149 per month (Wegovy pill 1.5 mg, Foundayo 0.8 mg) and run to $449 for higher-dose Zepbound KwikPen, down from list prices above $1,000. The White House announced the Eli Lilly and Novo Nordisk pricing agreements on November 6, 2025 and launched TrumpRx.gov on February 5, 2026; those announcements are the policy backdrop, but your price still depends on product, dose, insurance and offer expiry (several end December 31, 2026). Eligible Medicare patients may pay $50 per month through the GLP-1 Bridge (July 1, 2026 to December 31, 2027).

This guide covers prescription GLP-1 and related weight-management medications in the United States. Prices are in US dollars and are subject to change. Manufacturer savings programs have eligibility rules and may expire.

The cost of a GLP-1 medication in 2026 can range from under $200 per month for certain oral formulations or introductory self-pay offers to several hundred dollars per month for ongoing treatment. Insurance may lower the cost considerably, but coverage for obesity treatment is not guaranteed, even when a medication is medically appropriate.

This guide compares Wegovy (semaglutide), Zepbound (tirzepatide), Foundayo (orforglipron), Ozempic, Mounjaro and other prescription options, with an emphasis on what patients may actually pay.

Important: A manufacturer's or government's advertised price is not necessarily your final pharmacy price. Confirm the exact product, prescribed dose, dispensing method, insurance benefit and savings-program eligibility before starting treatment.

1. GLP-1 cost comparison: 2026 prices

The following are advertised US manufacturer prices or savings-program prices, not guarantees of availability or final checkout cost.

Medication Form Advertised self-pay price Key qualification
Wegovy Daily tablet $149–$299/month Price depends on dose; prescription and program restrictions apply.
Wegovy Weekly injection $199/month for eligible new patients' first two fills on specified starting doses; generally $349/month thereafter Introductory offer and pricing are subject to current terms.
Wegovy HD Weekly injection $399/month Self-pay price under current manufacturer terms.
Zepbound KwikPen Weekly injection $299, $399 or $449/month through the applicable 2026 self-pay offer Eligibility, dose, refill timing and program expiration apply.
Foundayo Daily tablet $149–$349/month Temporary reductions and refill-dependent offers affect certain doses.

Official pricing: NovoCare (Wegovy), Lilly (Zepbound), Lilly (Foundayo). These figures do not mean the medications are interchangeable. They have different active ingredients, doses, clinical evidence, indications and safety considerations.

Why some tables show different prices: a product may have a wholesale list price, an ordinary cash price, a temporary manufacturer offer and a separate price for patients with insurance. Those figures describe different payment situations. The official pricing page for the exact formulation is the final reference.

2. Why prices fell: the November 2025 White House pricing deal and TrumpRx

On November 6, 2025, the White House announced agreements with Eli Lilly and Novo Nordisk to cut what Americans pay for GLP-1 medicines. On February 5, 2026, it launched TrumpRx.gov, a federal website intended to route patients to the discounted prices. The details below come from the White House's own November 2025 fact sheet and February 2026 TrumpRx fact sheet. These are government announcements of what was agreed or launched. They are not pharmacy price lists, and this guide reports them without endorsing or criticizing the policy.

What was announced, and how it compares with current pricing

Product Nov 6, 2025 announcement Feb 5, 2026 TrumpRx launch Manufacturer pricing in this guide
Wegovy injection From $1,350 to $350 per month via TrumpRx From $1,349 to an average of $350, as low as $199 depending on dose $199 introductory / $349 standard; Wegovy HD $399
Wegovy pill Initial dose $150 per month if approved by FDA From $1,349 to as low as $149 depending on dose $149 (1.5 mg) to $299 (9 mg, 25 mg)
Ozempic (diabetes brand) From $1,000 to $350 via TrumpRx From $1,028 to an average of $350 Not a weight-management price; verify on the official page
Zepbound From $1,086 to an average of $346 via TrumpRx From $1,088 to an average of $346, as low as $299 depending on dose $299, $399 or $449 (KwikPen, dose-specific)
Orforglipron (Foundayo) Average $346 if approved; oral GLP-1 initial doses $150 Not itemized in the fact sheet text $149–$349 depending on dose
Medicare price and copay Medicare price of $245 for Ozempic, Wegovy, Mounjaro and Zepbound; beneficiary copay of $50 per month Not restated $50 per month through the Medicare GLP-1 Bridge (section 6)

Read across the columns and the pattern is consistent: the entry-level cash prices announced for oral products (about $150) and for the lowest injectable doses (about $199 to $299) match what manufacturers now advertise. The announced averages ($346 to $350) sit in the middle of a dose-based range, so higher doses cost more than the average and starting doses cost less.

What the fact sheets say beyond headline prices

  • Medicare and Medicaid: the November 2025 fact sheet states that the negotiated prices would let Medicare cover Wegovy and Zepbound for adults with obesity and related conditions for the first time, with a $50 monthly copay, and that state Medicaid programs would have access to the same prices.
  • New medicines: Lilly and Novo Nordisk agreed to guarantee most-favored-nation (MFN) prices on new medicines they bring to market, and to give every state Medicaid program access to MFN prices on their products.
  • Other drugs in the same deal: Trulicity at $389 per month (Lilly), Emgality at $299 per pen (Lilly), and insulin products such as NovoLog and Tresiba at $35 per month of supply (Novo Nordisk).
  • How patients reach the price: the February 2026 fact sheet says patients with valid prescriptions can use coupons printed or downloaded from TrumpRx.gov, or channels the manufacturer has integrated into the site, depending on the drug.
  • Manufacturing: Novo Nordisk committed an additional $10 billion to US operations and Lilly announced at least $27 billion in new US manufacturing investment.

What an announced price does not tell you: (1) TrumpRx is a route to cash prices, not insurance, so ordinary self-pay rules apply and purchases generally do not count toward your deductible. (2) Pill prices announced as "initial dose" prices rise with dose; Wegovy tablets reach $299 at the 9 mg and 25 mg doses. (3) Several manufacturer offers expire on December 31, 2026 or require a refill within 45 days. (4) Insurance coverage, prior authorization and state Medicaid decisions are separate from these cash prices. Always confirm on the manufacturer page the day you fill.

Record drugmaker revenue: what it does and does not mean for your price

On October 29, 2026, Bloomberg reported (subscription may be required) that several of the largest US drugmakers, including Eli Lilly, posted record third-quarter revenue and raised full-year forecasts, citing strong demand for products such as Zepbound despite the administration's pricing agreements. Bloomberg said Lilly's finance chief told analysts that growth in volume would more than make up for pressure on price. Lilly's own third-quarter release reports revenue of $24.4 billion, up 39% from a year earlier and driven primarily by Mounjaro and Zepbound, and CNBC reported Zepbound revenue of $5.35 billion for the quarter.

The White House, in a statement quoted by Bloomberg, describes the pricing deals as driving the largest drop in drug prices in decades. Bloomberg's reporting frames the earnings as showing little financial pain for manufacturers so far. Both can be true at once: patient-facing cash prices fell while company revenue rose on higher volume. For readers, three practical points follow:

  • Record revenue does not make the discounts unreal, and it does not make them permanent. The offers in section 3 still carry their own expiry dates and refill conditions. No source reviewed for this guide promises 2027 cash prices.
  • Medicare and Medicaid access is expected to widen. Bloomberg noted that Medicare is technically barred from covering weight-loss drugs and that the administration built a workaround in exchange for price concessions from Lilly and Novo Nordisk. Lilly's US chief said its obesity medicines should reach more Medicare and Medicaid beneficiaries next year at a lower price. That is company guidance, not a coverage guarantee for any individual.
  • Commercial insurance may not follow cash prices down. Reporting on the same call indicates Lilly expects prices in commercial plans to stay roughly stable overall. Falling cash prices therefore do not mean your employer plan's cost or coverage will change in step; verify your own benefit.

3. GLP-1 self-pay prices: what you need to know

Self-pay means paying for the medication outside your health insurance's prescription benefit. This can be useful when a plan excludes weight-management medicines, but the purchase ordinarily does not count toward the plan's deductible or out-of-pocket maximum.

2026 weight-loss drug guide infographic comparing GLP-1 prices

Wegovy self-pay pricing

Novo Nordisk's current US NovoCare Pharmacy pricing separates the oral tablet from the injectable products.

  • Wegovy pill: $149 per month for 1.5 mg, $199 for 4 mg, and $299 for 9 mg or 25 mg.
  • Wegovy injection: eligible new patients using the current introductory offer pay $199 per monthly fill for the 0.25 mg and 0.5 mg starting doses for two fills through December 31, 2026.
  • After the introductory injection offer: the current published self-pay price is $349 per month for standard pen doses, with different pricing for Wegovy HD.
  • Wegovy HD 7.2 mg injection: the published self-pay price is $399 per month.

Eligibility conditions apply. The introductory offer is not a promise of the same price for every dose or every subsequent refill. Check the current NovoCare price list and savings terms before filling a prescription.

Zepbound self-pay pricing

Eli Lilly offers a self-pay savings program for the single-patient-use Zepbound KwikPen. The current advertised offer is dose-specific:

KwikPen dose Advertised self-pay price Important condition
2.5 mg $299/month Starting dose; not an approved maintenance dose.
5 mg $399/month Prescription and program eligibility required.
7.5 mg $449/month Higher-dose offer and refill conditions apply.
10 mg $449/month Higher-dose offer and refill conditions apply.
12.5 mg $449/month Higher-dose offer and refill conditions apply.
15 mg $449/month Higher-dose offer and refill conditions apply.

For the 7.5 mg, 10 mg, 12.5 mg and 15 mg KwikPen doses, the offer requires a qualifying refill within 45 days of receipt of the preceding prescription. The self-pay savings card is scheduled to expire on December 31, 2026, and Lilly may change its terms. Without the applicable offer, the published regular monthly price for these higher doses is substantially higher: $499 for 7.5 mg and $699 for 10 mg, 12.5 mg or 15 mg.

The self-pay card is for eligible US or Puerto Rico residents aged 18 or older with a valid prescription. It is separate from insurance and cannot be used to have the same expense reimbursed by an insurer or counted toward an insurance deductible.

Check the official Zepbound savings page for the current rules. Do not assume the advertised $449 price is guaranteed for an entire year.

Foundayo self-pay pricing

Foundayo (orforglipron) is a once-daily oral GLP-1 receptor agonist approved in the United States in April 2026 for chronic weight management in eligible adults. Lilly's published pricing distinguishes regular prices from temporary offers.

Foundayo dose Regular monthly price Current offer where applicable
0.8 mg $149 $149
2.5 mg $199 $149 through December 31, 2026
5.5 mg $299 $199 through December 31, 2026
9 mg $299 $299
14.5 mg $349 $299 under the refill-dependent offer
17.2 mg $349 $299 under the refill-dependent offer

For the highest doses, the discounted price requires a qualifying refill within 45 days. The self-pay offer has an expiration date and may change. Additional taxes or fees may apply. See Foundayo's official pricing and coverage terms.

What about Ozempic and Mounjaro?

Ozempic (semaglutide) and Mounjaro (tirzepatide) are diabetes-brand products, whereas Wegovy and Zepbound are the corresponding brands specifically approved for weight management in eligible patients. The White House fact sheets list Ozempic among the products with reduced TrumpRx prices (about $350 on average), but that is a separate pricing track from the weight-management tables above.

Do not compare these brands only by sticker price. Insurance coverage may depend on whether a prescription is for type 2 diabetes or for weight management, the exact product and its FDA-approved indications. A prescription for one brand does not automatically qualify for a discount or coverage under another brand's program.

4. Oral GLP-1 pills: are they cheaper than injections?

In 2026, oral options for chronic weight management include Wegovy tablets and Foundayo tablets. Both broaden treatment choice, but their pricing structures and administration requirements differ. The 2025 White House announcement specifically cited a $150 initial-dose price for oral GLP-1s, and both products now advertise a $149 entry price.

Pill Price range Notes
Wegovy tablet $149–$299/month Contains oral semaglutide. Taken once daily with dose-dependent self-pay pricing. Follow the product's instructions about taking it with water and waiting before eating or drinking. Pricing
Foundayo tablet $149–$349/month Contains orforglipron. Taken once daily without the same food or water timing restrictions as oral semaglutide. Certain doses have temporary cash-pay discounts. Pricing

Does a pill automatically cost less?

No. Oral medicines can have a lower advertised entry price, but your ongoing cost depends on the prescribed dose, treatment duration, insurance benefits and current savings terms. Compare the expected cost of the maintenance dose, not just the introductory dose.

Also distinguish oral Wegovy from Rybelsus. Rybelsus is an oral semaglutide brand approved for type 2 diabetes; it should not be treated as an interchangeable, approved weight-loss substitute for Wegovy tablets.

Clinical note: price is only one factor in selecting a treatment. Expected benefits, contraindications, tolerability, administration preferences, other medical conditions and the clinician's assessment also matter. Do not combine GLP-1 medicines unless a qualified prescriber specifically directs treatment consistent with applicable prescribing guidance.

5. Does health insurance cover GLP-1 medications in 2026?

Sometimes, but coverage for type 2 diabetes and coverage for obesity are separate questions. A plan may cover Ozempic or Mounjaro for type 2 diabetes while excluding a weight-management prescription for Wegovy or Zepbound. Conversely, a plan may cover an obesity-labeled drug but impose restrictions on the product, dose, pharmacy or patient eligibility.

Employer and private insurance

The latest KFF 2025 Employer Health Benefits Survey found that 19% of firms with 200 or more employees offering health benefits covered GLP-1 medicines when used primarily for weight loss. Coverage was more common among the largest employers: 43% of firms with 5,000 or more employees reported coverage. Among firms that covered these drugs, 34% required a meeting with a dietitian, case manager or therapist, or participation in a lifestyle program.

These figures describe employer firms and their benefit plans, not the percentage of all individual insurance policies that cover treatment. They also show why it is unsafe to assume your own policy follows a national average. Source: KFF, 2025 Employer Health Benefits Survey.

Lower cash prices also change the comparison: when the self-pay price is close to a plan's copay or deductible exposure, ask your pharmacist to price both routes before choosing. Cash purchases generally will not count toward your deductible.

What insurance restrictions should you expect?

  • Prior authorization: your clinician may need to submit your BMI, related medical conditions, treatment history and other clinical information.
  • Eligibility criteria: coverage may depend on the product's indication, BMI thresholds, weight-related conditions or diabetes diagnosis.
  • Step therapy: the plan may require other treatment approaches or medications to be tried first, where permitted by the policy.
  • Formulary restrictions: a plan may prefer one product or dose over another.
  • Continuation requirements: renewal may depend on treatment response, adherence or updated clinical documentation.
  • Employer benefit exclusions: the employer's chosen plan may exclude anti-obesity medicines even if it covers other prescription GLP-1 drugs.

Coverage can also differ between a self-funded employer plan, a fully insured employer plan and an individual policy. The words "covered drug" on a manufacturer's website do not establish that your own plan will pay for your prescription.

How to verify coverage before starting

  1. Ask your insurer or pharmacy benefit manager whether the exact medication and formulation are covered for your intended indication.
  2. Request the plan's formulary, prior-authorization criteria, preferred alternatives and relevant exclusions.
  3. Ask for your estimated cost at the initial dose and the anticipated maintenance dose.
  4. Confirm whether the manufacturer savings card can be used with your particular insurance plan.
  5. Check whether authorization must be renewed and what happens if you change employers or plans.

Obtain the result in writing when possible. A pharmacy benefits representative can usually help explain the prescription benefit, while your clinician can assess medical eligibility and submit supporting documents.

6. Medicare GLP-1 coverage in 2026: the $50 monthly Bridge program

A major 2026 update: starting July 1, 2026, eligible Medicare beneficiaries can access selected GLP-1 medications for weight management through the temporary Medicare GLP-1 Bridge program, with a $50 monthly copayment. The program is scheduled to run through December 31, 2027. It operates outside the ordinary Medicare Part D benefit payment flow, so its copayment does not count toward the beneficiary's Part D out-of-pocket spending total.

Link to the 2025 White House announcement: the November 6, 2025 fact sheet announced a Medicare price of $245 for Ozempic, Wegovy, Mounjaro and Zepbound and a $50 monthly beneficiary copay, and said Medicare would cover Wegovy and Zepbound for obesity with related conditions for the first time. The $50 copay matches the Bridge copayment described here. The fact sheet does not describe the Bridge's eligibility rules, so use the CMS and Medicare.gov pages below for those.

Context from Bloomberg's October 29, 2026 reporting: Medicare is technically barred from covering weight-loss drugs, and the administration used a workaround tied to price concessions from Lilly and Novo Nordisk. That is consistent with the Bridge being a temporary program that sits outside ordinary Part D coverage.

Which products are included?

  • Wegovy: tablet or injection.
  • Foundayo: tablet.
  • Zepbound: KwikPen formulation only; the single-dose pen and single-dose vials are not included through the Bridge.

Who may qualify?

In general, the program is for adults aged 18 or older with Medicare Part D prescription coverage who satisfy the program's clinical requirements. The published BMI and medical-condition criteria include the following categories when starting treatment:

  • BMI of 35 or higher; or
  • BMI of 30 or higher with specified conditions, including heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a or more advanced chronic kidney disease; or
  • BMI of 27 or higher with specified conditions, including prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.

Other program restrictions apply. For example, people already receiving GLP-1 treatment covered through their Medicare drug plan are not eligible to switch that covered treatment into the Bridge. People whose Medicare drug plans should cover GLP-1 treatment for type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are directed to those regular plan benefits rather than the Bridge weight-management pathway.

Do not use the BMI criteria above as a substitute for the complete eligibility review. The program makes a formal coverage decision, including the relevant clinical criteria and documentation.

Does regular Medicare Part D now cover every GLP-1 for weight loss?

No. The Bridge is a specific temporary program with its own products, criteria and $50 copayment. It does not establish universal coverage for every GLP-1 medicine, every formulation or every person with obesity. Medicare may cover GLP-1 medicines under its regular prescription benefit for other qualifying FDA-approved indications, subject to the applicable plan's rules. Verify the indication, product and benefit pathway before assuming you qualify.

7. Medicaid, ACA Marketplace and other coverage

Medicaid

Coverage for obesity medications can vary by state and by the applicable Medicaid program. The November 2025 White House fact sheet says state Medicaid programs would have access to the negotiated GLP-1 prices and that Lilly and Novo Nordisk would offer every state Medicaid program MFN pricing. A later White House fact sheet (September 18, 2026) addresses lower drug prices for all 50 state Medicaid programs. Access to a lower price is not the same as a state choosing to cover obesity treatment, so do not assume that a prescription covered by a commercial insurer is also covered by Medicaid. Check the state's current drug formulary and prior-authorization requirements with the prescribing clinician or state Medicaid agency.

Manufacturer savings cards frequently exclude government-funded insurance beneficiaries. Always read the individual program terms before relying on a coupon.

ACA Marketplace and individual plans

Coverage depends on the policy and its prescription benefits. A plan's inclusion of diabetes medicines does not necessarily mean it covers branded medication for weight management. Check the plan documents and drug formulary rather than relying on a summary of benefits alone.

Manufacturer savings programs

  • Some offers require qualifying commercial insurance that covers the medication.
  • Some programs offer a cash-pay pathway for patients whose insurance does not cover the product or who have no insurance.
  • Government insurance beneficiaries may be excluded from certain commercial savings cards.
  • Offers may be limited by dose, the number of fills, refill intervals and expiration dates.

A savings card is not insurance and cannot be assumed to pay for clinical consultations, laboratory tests or other medical services.

8. How to reduce your GLP-1 cost

Compare the full treatment cost

Ask for the price of the actual product and dose prescribed. A low starting-dose offer may be attractive but may not reflect the long-term cost after dose escalation.

Use official price and coverage tools

Confirm the program's current terms on the day you fill the prescription. Some 2026 offers are explicitly time-limited.

Check more than one legitimate pharmacy

For a valid prescription, ask the dispensing pharmacy whether the available price reflects insurance, an eligible manufacturer offer or the cash price. Confirm the formulation, total quantity, delivery charges and any additional fees before accepting a quote.

Ask about assistance and alternative treatments

If branded treatment is unaffordable, discuss clinically appropriate alternatives with your healthcare professional. Depending on your diagnosis, medical history and goals, other evidence-based obesity treatments may be available. The cheapest medicine is not necessarily the best option for every patient.

Avoid unverified products

Be cautious of websites selling products described as research peptides, counterfeit prescription pens or unverified compounded formulations at unusually low prices. Products sold outside authorized supply channels may not provide the same assurance of identity, quality, handling or dosing as approved prescription medicines. Do not replace an approved prescription or change your dose solely because another online product appears cheaper.

9. Hidden costs and long-term budgeting

The pharmacy price is only part of the potential cost of treatment.

  • Clinical care: consultation fees, follow-up visits and any necessary laboratory testing may be billed separately.
  • Insurance administration: prior authorization, renewal reviews and requirements for clinical documentation may affect access and timing.
  • Nutrition and activity support: dietitian consultations, structured programs or resistance-training support may involve additional expenses.
  • Long-term treatment: plan for changing doses, changing insurance benefits and the possibility that a promotion may expire.

How much could a year cost?

Multiply the verified monthly price by 12 only when that price genuinely applies to all 12 fills. For example:

Monthly price 12 months Medicare Bridge comparison
$149 $1,788 $50 per month = $600 per year
$299 $3,588 $50 per month = $600 per year
$349 $4,188 $50 per month = $600 per year
$449 $5,388 $50 per month = $600 per year

These are simple arithmetic examples, not predictions of an individual's annual medication expenditure. They exclude consultations and other expenses, and they should not be used to project a temporary offer beyond its expiration date. The Medicare column applies only to eligible Bridge enrollees.

10. GLP-1 cost and coverage decision checklist

Before starting or renewing treatment, answer these questions with your prescriber and insurer:

  1. Which exact medication, formulation and dose are prescribed?
  2. What is the actual price for the first fill and the anticipated maintenance dose?
  3. Does my insurance cover this product for my specific indication?
  4. Is prior authorization required, and how will renewal be handled?
  5. Am I eligible for the manufacturer's current savings program, and is the same price listed on TrumpRx.gov?
  6. When does the savings offer expire, and are there refill-timing conditions?
  7. What is the expected total cost for six months and twelve months if the price changes?
  8. How will I manage treatment if coverage is denied or my insurance changes?

For eligible Medicare beneficiaries, add one more question: do I qualify for the Medicare GLP-1 Bridge, and is my prescribed formulation included?

11. Using this guide with AI assistants

Prices and offers change, so paste the current official price page into any assistant along with your question and ask it to cite the page it used.

  • Claude: ask it to build a six- and twelve-month cost comparison from the price tables above, flagging any offer that expires on December 31, 2026.
  • ChatGPT: ask it to draft a prior-authorization question list for your insurer based on section 5.
  • Gemini: ask it to compare the Medicare Bridge criteria in section 6 with your clinician's notes, then confirm on Medicare.gov.
  • Perplexity: ask it to find the latest TrumpRx.gov and manufacturer prices for your exact dose and to list its sources.

12. Frequently asked questions

How much do GLP-1 drugs cost per month in 2026?

It depends on the medication, dose, formulation, insurance benefit and savings offer. Current advertised US self-pay prices include $149–$299 per month for oral Wegovy, $149–$349 for Foundayo and dose-specific Zepbound KwikPen offers starting at $299. These are not universal prices or guarantees of eligibility.

Why did GLP-1 prices fall so much in 2026?

In November 2025 the White House announced pricing agreements with Eli Lilly and Novo Nordisk, and in February 2026 it launched TrumpRx.gov as a route to the discounted cash prices. The White House fact sheets describe reductions from list prices of roughly $1,000–$1,350 per month to about $350 on average, and as low as $149–$299 depending on product and dose. Manufacturer pricing pages remain the final reference for what you will actually pay.

What is TrumpRx and is it insurance?

TrumpRx.gov is a federal website that, according to the White House, gives patients with valid prescriptions access to discounted cash prices through coupons or manufacturer-run channels. It is not insurance: it is a way to reach manufacturer self-pay prices, and those purchases generally do not count toward an insurance deductible. Confirm terms with your insurer before paying cash.

Which GLP-1 pill is cheapest in 2026?

Wegovy tablets and Foundayo both have advertised entry-level self-pay pricing of $149 per month. Foundayo also has time-limited discounts on certain doses. Compare the dose you will actually take, the duration of any promotion and whether your insurance covers either product.

Does insurance cover Wegovy or Zepbound?

Some plans cover these medicines for eligible patients, while others exclude weight-management treatment or require prior authorization. Check the exact product, indication, pharmacy benefit, copayment and renewal requirements with your plan.

Can I get Zepbound for $299 per month?

The $299 price applies to the 2.5 mg KwikPen starting dose under the applicable self-pay program. Other doses have different prices. The 2.5 mg dose is not an approved maintenance dose, so do not budget for long-term treatment on the assumption that the starting price will continue.

Can Medicare cover GLP-1 medication for weight loss in 2026?

Eligible Medicare Part D beneficiaries may receive selected medications through the Medicare GLP-1 Bridge program for a $50 monthly copayment from July 1, 2026, through December 31, 2027. Clinical and product eligibility criteria apply; the program is not universal Medicare coverage for every GLP-1 medicine. The November 2025 White House fact sheet also announced a $50 monthly Medicare copay.

Are Ozempic and Wegovy the same medication?

Both contain semaglutide, but they are different branded products with distinct FDA-approved indications, dosing and coverage rules. A prescription for one does not automatically qualify for insurance coverage or manufacturer savings intended for the other.

Do manufacturer savings cards count toward my deductible?

Usually, purchases made outside insurance do not count toward your deductible or out-of-pocket maximum. Specific manufacturer-program terms govern how a payment is processed. Confirm with your insurer before paying cash.

Will GLP-1 prices decrease in 2027?

Future prices and coverage cannot be guaranteed. Some advertised offers currently expire on December 31, 2026. Recheck official manufacturer pages, TrumpRx.gov, insurance formularies and government program guidance before budgeting for 2027. Record drugmaker revenue reported on October 29, 2026 reflects higher volume, and Lilly's US chief said commercial-plan prices should stay roughly stable while Medicare and Medicaid access widens at lower prices; none of that guarantees a particular 2027 price for you.

Medical and financial disclaimer: This article is for general educational purposes and is not a substitute for medical advice, insurance-benefit verification or an individualized cost estimate. GLP-1 medicines require appropriate prescribing and monitoring. Never start, stop, combine or change the dose of a prescription medicine solely to save money without discussing the decision with your treating clinician. Government fact sheets are quoted as announcements of policy and prices; they are not guarantees of what any patient will pay.

Affiliate disclosure: this site participates in affiliate programs, including The Wellness Company (code ONEDAYMD). Links to those services in the knowledge graph below may earn a commission at no cost to you. Pricing information in this guide is not influenced by affiliate relationships.

Sources and further reading

  1. The White House: Fact Sheet, Most-Favored-Nation Pricing (November 6, 2025). Announced Eli Lilly and Novo Nordisk GLP-1 pricing, Medicare price and $50 copay, Medicaid access.
  2. The White House: Fact Sheet, Launch of TrumpRx.gov (February 5, 2026). TrumpRx launch, dose-based Wegovy and Zepbound price ranges.
  3. NovoCare: Wegovy costs, coverage and savings resources. Official tablet and injection prices, introductory offers and eligibility requirements.
  4. Eli Lilly: Zepbound savings and insurance options. Current KwikPen self-pay and insurance savings terms.
  5. Eli Lilly: Foundayo coverage and savings. Dose-specific prices, cash-pay offers and eligibility terms.
  6. Bloomberg: Drugmakers Shrug Off Trump Pricing Pressure With Record Revenue (October 29, 2026). Record Q3 revenue, Lilly volume-versus-price commentary, Medicare workaround. Subscription may be required.
  7. Eli Lilly: Third-quarter 2026 financial results (October 29, 2026). Primary source for Lilly revenue and product figures.
  8. CNBC: Eli Lilly Q3 2026 earnings (October 29, 2026). Zepbound quarterly revenue.
  9. Medicare.gov: Weight-loss drugs. Medicare GLP-1 Bridge program overview and beneficiary eligibility.
  10. CMS: Medicare GLP-1 Bridge. Official program dates, payment rules and coverage requirements.
  11. KFF: 2025 Employer Health Benefits Survey. Employer coverage findings and utilization-management requirements.
  12. US FDA: Foundayo approval. Official approval and indication information.

GLP-1 knowledge graph

OneDayMD editorial policy: Medication pricing and coverage information is reviewed against primary sources where possible. Manufacturer offers can change after publication; readers should verify the latest applicable terms before making a treatment or financial decision. Last updated November 6, 2026 to add the White House most-favored-nation pricing announcements and October 2026 drugmaker earnings context.

Comments

Post a Comment

Popular posts from this blog

GLP-1 Hub 2026: Approved Drugs, Pills vs Injections, Retatrutide & Safety

Image
Home › GLP-1 Hub By Dr. Frank Yap, MD  |  Last updated: November 2026  |  Purpose: evidence and safety education, not individual medical advice Quick Answer GLP-1 therapy now includes injections and, since 2025–2026, two FDA-approved pills : oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron) , approved April 1, 2026 as the first non-peptide oral GLP-1 for weight management.  The 5 November 2026 Science special issue (“GLP-1 and Beyond”) examines how GLP-1 receptor agonists and related metabolism-targeting drugs affect systems beyond classic metabolic disease—especially the brain—while highlighting the shift toward multi-receptor agents. Retatrutide is not approved anywhere ; it remains in Phase 3 testing. Compounded and gray-market GLP-1 or peptide products are not FDA-approved, and the FDA issued warning letters to telehealth compounders in March 2026. Any GLP-1 plan should run through a licensed physician and a regu...
Read more

How to Prevent Muscle Loss on GLP-1 Drugs: Protein, Resistance Training & Body Composition Guide (2026)

Image
Home › GLP-1 Hub > GLP-1 Muscle Loss By Dr. Frank Yap, MD  |  Last updated: October 2026  |  Purpose: evidence and safety education, not individual medical advice GLP-1-based medicines have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as the scale goes down, an important question follows: How much of the weight being lost is fat, and how much is lean tissue? This matters because long-term health is not determined by body weight alone. Preserving skeletal muscle, strength, physical function and nutritional adequacy is particularly important during substantial weight loss. The good news is that current evidence does not support the idea that GLP-1 therapies simply “eat away” muscle. Most weight lost with semaglutide and tirzepatide is fat mass. At the same time, measurable reductions in lean mass can occur, particularly during large or rapid weight loss. The ...
Read more

Start GLP-1 Weight Loss in 2026: Compare Wegovy, Zepbound, Foundayo & Oral Options

Image
By Dr. Frank Yap, MD  |  Published: September 28, 2026  |  Last updated: October 2026  |  Reference: U.S. FDA labeling  |  Purpose: evidence and safety education, not individual medical advice Quick Answer In the U.S. in 2026, adult weight-management GLP-1 options include Wegovy (weekly injection), Wegovy HD 7.2 mg (weekly, only after 2.4 mg is tolerated for 4+ weeks), the Wegovy pill (daily), Zepbound (tirzepatide, weekly) and Foundayo (orforglipron, daily pill). The only direct head-to-head trial, SURMOUNT-5, found -20.2% weight loss with tirzepatide vs -13.7% with semaglutide at 72 weeks, but pills and injections should not be ranked across different trials. Pick by goal (weight, heart risk, sleep apnea, liver), route, tolerability and cost, protect muscle with protein and resistance training, and plan for long-term maintenance because weight re...
Read more

GLP-1 Manual 2026: The Complete Guide to GLP-1 Drugs, Benefits, Risks, Dosing, Muscle Loss & Long-Term Strategy

Image
Updated November 2026 GLP-1 therapy has moved far beyond the simple phrase “weight-loss drugs.” Semaglutide, tirzepatide and newer oral and multi-receptor therapies are reshaping obesity, diabetes and cardiometabolic care. But a useful GLP-1 guide needs two columns: what these medicines can do, and what they can cost if treatment is poorly matched, escalated too quickly, or accompanied by inadequate nutrition and physical activity. This GLP-1 manual brings the major evidence together in one place: the drug family, approved 2026 therapies, emerging candidates, expected weight loss, cardiovascular and kidney outcomes, liver and sleep-apnea data, adverse effects, contraindications, oral contraceptive issues, peri-procedural considerations, muscle and bone preservation, monitoring and what happens when treatment is stopped. The central idea: GLP-1 therapy should not be judged by the scale alone. The clinically meaningful goal is better health wit...
Read more

GLP-1 and Beyond: What the Evidence Shows on Brain Health, Cancer Risk, Addiction and Next-Generation Drugs - Science Special Issue (2026)

Image
Quick Answer The 5 November 2026 Science special issue (“GLP-1 and Beyond”) examines how GLP-1 receptor agonists and related metabolism-targeting drugs affect systems beyond classic metabolic disease—especially the brain—while highlighting the shift toward multi-receptor agents. Observational data link these drugs to lower dementia risk in some metabolic populations, but large Alzheimer’s trials (EVOKE/EVOKE+) have not shown clinical benefit. Cancer-risk reductions appear largely tied to weight loss and related changes rather than proven intrinsic anticancer activity. Addiction research is promising but early. Key limitations include gastrointestinal effects, muscle loss, variable response, and weight regain after stopping. The issue stresses the need for better mechanistic studies, rigorous trials, and broader access strategies. Background: What the Special Issue Covers The package (introduction DOI: 10.1126/science.aen0869 ) includes three Reviews, two Perspectives, and a Policy...
Read more

Healthy Lifestyle and Longevity (2026): The Evidence on Diet, Exercise, Supplements & Anti-Aging Drugs

Image
By Dr. Frank Yap, MD | Medically reviewed by One Day MD Review Team | Originally published: August 24, 2026 | Last updated: October 2026 Quick Answer: A healthy lifestyle may add years to life, and potentially a decade or more in some populations, but no scientifically valid number applies to everyone. The biggest gains come from not smoking, regular physical activity, a high-quality diet, a healthy body weight, and controlled cardiovascular and metabolic risk factors . One influential U.S. analysis projected about 14 more years for women and 12 for men at age 50 for people with five low-risk habits versus none, but that is an observational estimate, not a guarantee. Supplements and anti-aging drugs are not proven to add a specific number of years. Preventing falls and injury also protects healthspan: balance and strength training is the best-supported strategy. In this guide What the Best Evidence Shows Other Studies Point the Same Way How Much Does Each Lifestyle Facto...
Read more

Retatrutide and Muscle Loss: What the Research Shows and How to Preserve Muscle (2026)

Image
Does retatrutide cause muscle loss? The available evidence suggests that retatrutide-associated weight loss includes a reduction in lean mass, as occurs with other effective obesity treatments. However, the available studies do not establish how much actual skeletal muscle an individual will lose, whether the loss affects muscle function, or how much can be prevented through nutrition and exercise. In a published Phase 2 body-composition substudy involving adults with type 2 diabetes, researchers observed substantial fat-mass reductions alongside reductions in lean mass. The results do not show that retatrutide uniquely damages muscle, but they also do not justify assuming that very large weight losses will preserve muscle automatically. The practical priority is to pursue fat loss while preserving strength, physical function, adequate nutrition, and as much useful muscle as possible . Evidence updated October 2026. This article is educational and is not a substitute for ind...
Read more

Semaglutide vs Tirzepatide Muscle Loss: Which Preserves More Lean Mass?

Image
Updated October 2026 Semaglutide and tirzepatide can produce substantial weight loss, but an important question has emerged alongside the popularity of GLP-1-based obesity medicines: How much of the weight lost is fat, and how much is lean mass? The question is more complicated than it first appears. Studies of semaglutide and tirzepatide show that both drugs reduce fat mass and also reduce lean mass during weight loss. However, lean mass is not synonymous with skeletal muscle , and results from separate trials cannot be interpreted as a direct head-to-head comparison of muscle preservation. A 2026 systematic review and meta-analysis of 20 randomized controlled trials involving 15,782 participants estimated that lean mass accounted for approximately 35.2% of weight lost with semaglutide and 25.4% with tirzepatide . However, the authors did not establish that tirzepatide preserves functional skeletal muscle better than semaglutide. The analysis also found that addin...
Read more

Oral Wegovy vs Foundayo vs Weekly Injections: Which Is Best for Weight Loss in 2026?

Image
Published: September 6, 2026  |   Last updated: October 2026  |   By: One Day MD Editorial Team The obesity-treatment landscape has changed significantly with the arrival of oral GLP-1 medicines. People who previously had to choose between weekly injections, daily lifestyle changes, and other weight-management treatments now have additional prescription options. Two important oral treatments are Wegovy tablets (semaglutide 25 mg) from Novo Nordisk and Foundayo (orforglipron) from Eli Lilly. Both are taken daily, but they contain different active ingredients and have different administration requirements. Weekly injections remain important alternatives. These include standard-dose Wegovy, higher-dose Wegovy HD in the United States, and tirzepatide sold as Zepbound for weight management in the United States. Which option is best depends on the amount of weight loss needed, convenience, tolerability, other medical conditions, cost, and treatme...
Read more